Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.

Blood - 15 Sept 2007

Wang Lisheng, Wang Jie, Blaser Bradley W, Duchemin Anne-Marie, Kusewitt Donna F, Liu Tom, Caligiuri Michael A, Briesewitz Roger

Abstract excerpt

Entry into the cell cycle is mediated by cyclin-dependent kinase 4/6 (CDK4/6) activation, followed by CDK2 activation. We found that pharmacologic inhibition of the Flt3 internal tandem duplication (ITD), a mutated receptor tyrosine kinase commonly found in patients with acute myelogenous leukemi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin D2
Share to Cyclin-Dependent Kinase 4
Share to Cyclin-Dependent Kinase 6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p27

Share to G1 Phase

Share to Leukemia, Myeloid

Share to Morpholines

Share to Pyrroles

Source

Identifiers

PMID: 17537993
DOI: 10.1182/blood-2007-02-071266

Genes

CDK4
CDK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17537993-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.PMID 17537993Read ↗

Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising ApproachesSemantic proximity Read ↗

Targeting cell cycle regulators in hematologic malignanciesSemantic proximity Read ↗

Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.Semantic proximity Read ↗

CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated CytotoxicitySemantic proximity Read ↗

Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.Semantic proximity Read ↗

An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia.Semantic proximity Read ↗

Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα.Semantic proximity Read ↗

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)Semantic proximity Read ↗

Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 InhibitionSemantic proximity Read ↗

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutationsSemantic proximity Read ↗

Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemiaSemantic proximity Read ↗

Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.